VEGF-A inhibition using bevacizumab failed to inhibit VM in breast cancer cells in vitro, furthermore, sunitinib, a multi targeting anti-VEGFR inhibitor, even promoted VM in breast cancer mouse models (Dey et al., 2015; Sun et al., 2017). The gene discussed is VEGFA; the disease is breast carcinoma.